| 国银河证券 | CGS 《二十届三中全会公报》对 A 股市场投资的战略指导 分析师:杨超 研究助理:王雪莹、周美丽 www.chinastock.com.cn 证券研究报告 诸务必阅读正文最后的中国银河证券股份有限公司免费声明 策略研究 · 专题报告 《二十届三中全会公报》对 A 股市场投资的战略指导 核心观点: 《二十届三中全会公报》主要内容:二十届三中全会于 2024 年 7 月 15 日 o 至 18 日召开,审议通过了《中共中央关于进一步全面深化改革、推进中国式 现代化的决定》。(1)关于目标:全会指出,进一步全面深化改革的总目标 是继续完善和发展中国特色社会主义制度,推进国家治理体系和治理能力现 代化。到二○三五年,全面建成高水平社会主义市场经济体制,中国特色社会 主义制度更加完善,基本实现国家治理体系和治理能力现代化,基本实现社会 主义现代化,为到本世纪中叶金面建成社会主义现代化强国奠定坚实基础。到 二○二九年中华人民共和国成立八十周年时,完成本决定提出的改革任务。 (2)对进一步全面深化改革的系统部署:强调构建高水平社会主义市场经济 体制,健全推动经济高质量发展体制机制,构建支持全面创新体制 ...

Financial Data and Key Indicators Changes - The global photovoltaic (PV) installed capacity is expected to reach 490GW in 2024, representing a 21% year-on-year increase, with domestic demand projected to grow steadily [2][14] - The domestic market is anticipated to add 240GW in 2024, a year-on-year increase of 11%, while the first five months of 2024 saw a 29.3% increase in new installations [14][16] Business Line Data and Key Indicators Changes - The silicon material sector is expected to produce over 2 million tons in 2024, with prices dropping to 35,000-40,000 RMB per ton, indicating a significant decline in profitability [2] - The inverter market is benefiting from the rise in energy storage and overseas markets, with a notable increase in demand from emerging markets [2][16] Market Data and Key Indicators Changes - In the first quarter of 2024, ground-mounted installations accounted for 47.9% of new capacity, with significant contributions from commercial and residential sectors [9] - The average bidding price for components has dropped below 0.9 RMB/W, with N-type and bifacial modules gaining market share [8][9] Company Strategy and Development Direction and Industry Competition - The industry is entering a phase of supply clearing, with overcapacity in the main supply chain leading to pressure on profitability, particularly in the silicon wafer and module manufacturing sectors [2][4] - The company is focusing on new technologies such as N-type cells and perovskite materials to enhance efficiency and reduce costs, with expectations for significant advancements in the coming years [2][4] Management's Comments on Operating Environment and Future Outlook - Management noted that the high growth phase for PV demand has passed, and the industry is now entering a period of stable growth, with supply-demand balance expected to improve [6][14] - The management expressed concerns about potential policy changes and competition intensifying, which could impact future growth [2][4] Other Important Information - The company highlighted the importance of technological innovation in maintaining competitive advantages, particularly in the inverter and auxiliary materials sectors [2][4] - Risks include intensified competition, grid absorption issues, and unexpected changes in PV policies that could affect new installation volumes [2][4] Q&A Session Summary Question: What are the expectations for the domestic PV market in 2024? - The domestic market is expected to add 240GW in 2024, with a steady growth trajectory despite potential short-term bottlenecks due to grid absorption issues [14] Question: How is the company addressing the challenges in the silicon material sector? - The company is monitoring the price trends closely and is prepared to adjust production levels in response to market conditions to mitigate profitability pressures [2] Question: What are the key technological advancements the company is focusing on? - The company is investing in N-type cell technology and perovskite materials, which are expected to enhance efficiency and reduce costs significantly in the near future [2][4]

Financial Data and Key Indicators Changes - The overall market size of China's automotive travel industry is projected to grow steadily, with an estimated market size of 8.54 trillion yuan in 2023, increasing to 9.30 trillion yuan by 2030 [11] - The penetration rate of shared travel is expected to rise from 5.3% in 2023 to 6.0% by 2030, indicating a growing trend towards shared mobility solutions [11] Business Line Data and Key Indicators Changes - The B-end shared travel market size is forecasted to reach 4.56 trillion yuan in 2025, with a year-on-year growth rate of 5% [11] - The Robotaxi market size is expected to grow significantly, with projections of 0.5 billion yuan in 2026 and reaching 4161 billion yuan by 2030, capturing a substantial share of the shared travel market [11] Market Data and Key Indicators Changes - The number of registered ride-hailing drivers in China increased from 4.07 million in March 2022 to 7.03 million by May 2024, reflecting a strong demand for shared mobility services [8] - The private car ownership is projected to peak by 2028, with the Robotaxi market expected to replace a significant portion of this segment [10] Company Strategy and Development Direction and Industry Competition - The industry is witnessing a shift towards AI-driven smart transformation, with Robotaxi emerging as a preferred direction for commercialization [3] - Companies like Tesla are positioned as leaders in the Robotaxi space, leveraging self-developed driving software and hardware solutions to create a positive cycle of technology, traffic, and profitability [2] Management's Comments on Operating Environment and Future Outlook - The management emphasizes that the combination of policy support, technological advancements, and operational improvements will drive the scalability of Robotaxi services, with 2026 anticipated as a pivotal year for mass production [2] - The management also highlighted the importance of reducing operational costs and improving efficiency through the deployment of Robotaxi services [45] Other Important Information - The Robotaxi industry is supported by various government policies aimed at promoting smart transportation and the integration of vehicle-road-cloud systems [12] - The competitive landscape includes major players like Baidu and various OEMs, all vying for market share in the burgeoning Robotaxi sector [30] Q&A Session Summary Question: What are the key drivers for the growth of the Robotaxi market? - The growth is primarily driven by policy support, technological advancements in autonomous driving, and the operational efficiency of Robotaxi services [2][3] Question: How does the company view the competition in the Robotaxi space? - The company acknowledges the competitive landscape but believes that its technological edge and strategic partnerships will position it favorably against competitors [30] Question: What are the anticipated challenges for Robotaxi deployment? - Key challenges include regulatory hurdles, the need for a standardized approval process, and the establishment of clear liability frameworks for autonomous vehicles [48]

行业报告 | 行业深度研究 证券研究报告 2024年07月16日 生猪专题:猪周期到哪了?板块预期差在哪里? 作者: 分析师 吴立 SAC执业证书编号:S1110517010002 分析师 陈潇 SAC执业证书编号:S1110519070002 联系人 陈炼 行业评级: 上次评级: 强于大市 ( 评级) 维持 强于大市 1 请务必阅读正文之后的信息披露和免责申明 ➢ 猪周期到哪了?板块预期差在哪里? 一、 供需展望:供需剪刀差放大,重视大周期 1)供应端:①生猪理论供应量持续减少。本轮全国能繁母猪存栏量累计最大去化约11%(截止2024年5月),上一轮周期(2021-22年)农业部累计最 大去化幅度为9%(对应22年周期猪价高点28元/kg+),三元母猪淘汰优化极大弥补了21年实际产能去化,而近两年行业效率未出现大幅提升,今年生猪 供应压力或持续缓解;②活体库存正常。今年行业二育多为滚动出栏(行业对猪价谨慎看好,且二育头均盈利水平较为理想),截止7月11日,150kg以 上生猪出栏占比仅为4.89%,处于近几年较低位,大猪库存处于正常状态。③冻品压力有限。自23年10月来,每月进口猪肉量均低于10万吨/月,为 ...

证券研究报告 | 公司深度报告 2024 年 07 月 08 日 五粮液(000858.SZ) 重新认识五粮液 | --- | --- | --- | --- | --- | --- | |--------------------|--------|--------|--------|---------|---------| | 财务指标 | 2022A | 2023A | 2024E | 2025E | 2026E | | 营业收入(百万元) | 73,969 | 83,272 | 91,674 | 102,033 | 114,277 | | 增长率 yoy(%) | 11.7 | 12.6 | 10.1 | 11.3 | 12.0 | | 归母净利润(百万元) | 26,690 | 30,211 | 33,874 | 38,298 | 43,581 | | 增长率 yoy(%) | 14.2 | 13.2 | 12.1 | 13.1 | 13.8 | | ROE(%) | 24.0 | 23.8 | 23.7 | 23.4 | 23.1 | | EPS 最新摊薄(元) | 6.88 | 7.78 | 8. ...

Financial Data and Key Metrics - The company has already put into production 30,500L capacity, with an additional 36,000L capacity expected to be completed by the end of July [5] - The global biopharmaceutical market is projected to reach approximately $70 billion in the next 5 years, with 60% in the US, 30% in Europe, and 10% in other regions [6] Business Line Data and Key Metrics - TOFIDENCE (tocilizumab injection) and Avzivi® (bevacizumab injection) are being commercialized in Europe and the US, with pricing strategies differing from competitors [3] - BAT8006, a FRα ADC product, has shown superior anti-tumor activity in platinum-resistant ovarian cancer patients with FRα expression levels of TPS≥1% [19] - Betanine® (bevacizumab citrate injection) has shown a 43% risk reduction in clinical studies compared to 16% for similar products [12] Market Data and Key Metrics - The US is the primary market for biologics, with recent FDA and CMS policies favoring the rapid entry of biosimilars into the market [6] - TOFIDENCE began sales in the US in May, with market expansion expected to take time [15] Company Strategy and Industry Competition - The company is preparing to compete in global markets, particularly in the face of potential centralized procurement in China [1][9] - The company is focusing on expanding its production capacity and preparing for market entry of new products [5][12] Management Commentary on Operating Environment and Future Outlook - The company believes that the biopharmaceutical sector will be less affected by US election outcomes, as the focus is more on industries like electric vehicles and electronics [13] - The company is optimistic about the supportive policies for innovative drugs and biopharmaceuticals in China, particularly in Guangzhou [14] Other Important Information - BAT8006 received FDA IND approval in March for Phase II clinical trials in platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer [8] - The company is exploring the feasibility of combining BAT8006 with bevacizumab and PD1 for treatment [8] Q&A Session Summary Q1: Impact of potential US tariffs on Chinese goods and company strategy - The company is prepared to compete in centralized procurement scenarios, focusing on production cost competitiveness [1] Q2: Future centralized procurement possibilities for adalimumab and bevacizumab - The company is considering global market competition and preparing for potential centralized procurement [9] Q3: Support measures for innovative drugs in China - The company highlights supportive policies at both national and local levels, particularly in Guangzhou [14] Q4: Sales progress of tocilizumab and bevacizumab in Europe and the US - The company notes that pricing strategies differ from competitors and that market expansion will take time [3][15] Q5: Impact of US-China relations on BD transactions and agreements - The company has not observed any significant impact on BD transactions due to US-China relations [2] Q6: Current and future production capacity - The company has 30,500L capacity in production and expects to complete an additional 36,000L by the end of July [5] Q7: Sales strategy and pricing for tocilizumab and bevacizumab in Europe and the US - The company's partners determine the commercialization strategy, with pricing differing from competitors [3] Q8: Market share in regions outside the US - The company did not provide specific details on market share outside the US [17] Q9: Timeline for biosimilar entry into the US market - It may take six months or more for a biosimilar to enter the US market after approval, with additional time needed to gain market share [20] Q10: Commercialization plans for bevacizumab - The company did not provide specific details on commercialization plans for bevacizumab [4] Q11: Market sales expectations for bevacizumab - The company notes uncertainty in market expectations due to factors like医保准入 [21] Q12: Advantages of FRα ADC and future clinical development plans - BAT8006 has shown superior anti-tumor activity and safety in early data, with plans for further clinical trials [19]

Financial Data and Key Metrics Changes - The company has seen a significant increase in R&D expenses, reaching 360 million yuan, with two-thirds of this amount allocated to biopharmaceuticals, indicating a strong focus on this area [2][4] - The company anticipates a net profit margin of approximately 15% to 20% for 2024 compared to 2023, reflecting a positive outlook on profitability despite market challenges [28] Business Line Data and Key Metrics Changes - The company aims to expand its product offerings from over 50 to 120 by 2027, focusing on small molecule drugs, which have been a significant contributor to gross profit [1][4] - The company is actively developing three insulin products, with expectations for clinical trials to progress as planned, indicating a robust pipeline in the diabetes treatment segment [11] Market Data and Key Metrics Changes - The company predicts a gradual recovery in raw material prices, with expectations of a 10% increase by early next year, following a period of price stabilization [14][22] - The biopharmaceutical market is expected to see significant growth, with the company projecting that biosimilars could capture 70% to 80% of the market by 2030 [33] Company Strategy and Development Direction - The company is positioning itself as a key player in the U.S. biopharmaceutical market, emphasizing rapid product development and high-quality standards [1][4] - The strategy includes a focus on collaboration in R&D, particularly in the biopharmaceutical sector, to enhance innovation and market competitiveness [2][4] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the approval timelines for key products, including a biosimilar expected to be approved in Q4 of this year, which could generate significant revenue [8][9] - The management highlighted the importance of maintaining price stability in a competitive market, indicating a preference for sustainable profit margins over aggressive pricing strategies [49][54] Other Important Information - The company has successfully resolved patent challenges for key products, which is expected to facilitate smoother market entry and sales [7][8] - The management noted that the global market for biopharmaceuticals is becoming increasingly competitive, with a focus on quality and compliance as critical success factors [4][5] Q&A Session Summary Question: What is the market outlook for the biosimilar Adalimumab? - The company anticipates that biosimilars will significantly increase their market share, potentially reaching 70% to 80% by 2030, driven by the expiration of patents and increased competition [33][35] Question: How does the company plan to manage its inventory levels? - Management clarified that while inventory levels are currently high, they are not overly concerning, as they are in line with industry standards and will be managed strategically to avoid price wars [42][44] Question: What is the company's strategy regarding pricing in a competitive environment? - The company aims to maintain price stability and avoid aggressive price competition, focusing instead on quality and sustainable profit margins [49][54]

Financial Data and Key Metrics Changes - The report highlights the overall growth trend in the Southeast Asian automotive market, indicating a significant increase in consumer purchasing power and market potential [65][70] - The automotive industry in Southeast Asia is expected to experience a new peak driven by economic recovery and replacement demand, with historical sales levels being approached [70] Business Line Data and Key Metrics Changes - The report emphasizes the importance of product localization, with Japanese automakers tailoring their offerings to meet the specific preferences of Southeast Asian consumers, such as pickups in Thailand and MPVs in Indonesia [24][41] - The market share of Japanese automakers in Southeast Asia remains dominant, with a reported 68.1% market share in 2023, showcasing their strong presence in the region [28] Market Data and Key Metrics Changes - The automotive demand in ASEAN countries has been rapidly increasing, with significant growth in vehicle ownership per thousand people, particularly in Thailand, Malaysia, and Indonesia [21][24] - The report notes that the electric vehicle market in Southeast Asia is still in its infancy, with traditional fuel vehicles being the primary focus for Japanese automakers [44] Company Strategy and Development Direction - The strategy for entering the Southeast Asian market includes establishing local production facilities, enhancing dealer networks, and leveraging local partnerships to build brand influence [4][35] - Japanese automakers are focusing on a comprehensive localization strategy, which includes not only vehicle assembly but also local parts production to reduce costs and improve delivery efficiency [49][51] Management Comments on Operating Environment and Future Outlook - The management comments on the favorable economic conditions in Southeast Asia, which are expected to enhance the automotive market's growth potential, particularly as the middle class expands [65][70] - There is an acknowledgment of the challenges posed by the competitive landscape and the need for continuous adaptation to local market conditions [5][65] Other Important Information - The report outlines the risks associated with the automotive market, including potential declines in demand for new energy vehicles and the impact of trade protectionism in export regions [5] - The importance of establishing a robust after-sales service network and financial services to enhance customer loyalty and brand recognition is emphasized [56][59] Q&A Session Summary Question: What are the key factors driving the growth of the automotive market in Southeast Asia? - The growth is driven by stable economic conditions, increasing consumer purchasing power, and a significant potential for vehicle ownership expansion in the region [65][70] Question: How are Japanese automakers adapting their strategies for the Southeast Asian market? - Japanese automakers are focusing on product localization, establishing local production facilities, and enhancing dealer networks to better meet local consumer preferences [4][35][41] Question: What challenges do Japanese automakers face in the Southeast Asian market? - Challenges include competition from local and international brands, potential declines in demand for new energy vehicles, and the need to navigate trade protectionism [5][70]

Financial Data and Key Metrics Changes - In the first half of 2024, the company expects to achieve revenue between 1.05 billion to 1.15 billion, representing a year-on-year growth of 45% to 59% [5] - The expected net profit attributable to shareholders is between 55 million to 67 million, indicating a year-on-year increase of 56% to 90% [5] Business Line Data and Key Metrics Changes - The second growth curve, which includes certified enterprise developers and individual developers, has shown significant growth compared to the first quarter, with a substantial increase in revenue [16] - The first growth curve, primarily in the special fields, is experiencing stable growth, particularly in government business, which is developing rapidly [17] Market Data and Key Metrics Changes - The company is expanding its online platform, which now covers over 70 industries, while offline services focus on special fields, government, and enterprises [23] - The government business is a key area of growth, with a focus on smart government initiatives, including transportation, water conservancy, public safety, and natural resource monitoring [32] Company Strategy and Development Direction - The company is focusing on digital transformation for enterprises, particularly large state-owned enterprises in the energy sector, to meet high safety production requirements [64] - The company is also exploring commercial aerospace applications, with a strategic plan for satellite constellations announced recently [83] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the pressure on cash flow, which is expected to remain negative in the first half of the year, with a focus on improving collection in the second half [49] - The company is facing challenges in government payment collections due to fiscal pressures, but is strategically selecting projects to enhance relationships with government clients [51] Other Important Information - The company is diversifying its risk by maintaining multiple qualifications across its subsidiaries, which helps mitigate the impact of stricter qualification reviews in the industry [40] - The establishment of new military organizational structures is viewed positively, as it may lead to new opportunities and product iterations [74] Q&A Session Summary Question: How is the order situation in the special fields? - Management noted that while there have been adjustments in the special fields, ongoing projects are still progressing, and overall order levels remain satisfactory [35] Question: How does the company view the competitive landscape with some competitors losing qualifications? - Management believes that while there may be opportunities for market share gain, they are focused on their own path and maintaining their qualifications [70] Question: What is the outlook for cash flow and collection in the second half of the year? - Management indicated that negative cash flow is typical for the first half, with expectations for improvement in collections as government projects progress [49][50] Question: What is the company's strategy regarding commercial aerospace and satellite constellations? - The company plans to primarily pursue acquisitions to expand its capabilities in commercial aerospace rather than developing satellites from scratch [97]

2024 年 07 月 19 日 00:44 发言人 00:00 发言人 01:02 发言人 01:37 发言人 02:07 发言人 04:24 更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 中国天楹 20240718_原文 我们今天邀请中国信的董事长助理肖总，我给大家来看一下天元的 20 年业绩半年度的业绩预告 的一个交流会。我看肖总已经到了，肖总您先给大家对 24 年上半年，包括二季度的一个情况做 一个介绍。赵宝兄弟，谢谢尊敬的各位投资者，大家上午好啊。首先感谢大家对中国电影的关 注。我现在这几天市场也不是很好，大家还能够抽出这个时间来听我这样一个电话会。 发言人 00:35 我们中心应该是在 7 月 10 号发布了 2024 年的半年报。2024 年的预计的上半年的一个净利润， 大概在 3.52 亿到 3.9 亿次区间。那就去年同期的话应该是有一个大幅的增长。我想 2021 年，中 国天银是提出了这么一个叫环保加新能源，以及推进国内国际双循环的这么一个发展战略。 以整个一季报为例的话，我们可以会看出来，就整个我们的从财务层面上面反映出来的，其实 还是主要的。这个是我们的环保的业务。因为我们新 ...